The levels of biomarkers like Lp-PLA2 activity and hsCRP were elevated among the subjects with metabolic syndrome and without atherosclerotic diseases.
Metabolic syndrome (MS) is a group of cardiovascular risk factors associated with increased levels of inflammatory markers. A comparison of levels of inflammatory markers of metabolic syndrome (Lp-PLA2 and hsCRP) was evaluated and reported.
Both high sensitivity C-reactive protein (hsCRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2) are the predictors of MS and deemed to be independent of each other.
Findings: high sensitivity C-reactive protein (hsCRP)
- Mean hsCRP levels were 2.1 +/-2.2 mg/L
- Gender of the subject did not show significant difference in their mean hsCRP levels
- Had a significant and direct correlation with BMI, waist circumference, blood glucose, systolic BP, non-HDL-C, and fibrinogen
- Had significant and inverse correlation with HDL-C
Findings: Lipoprotein-associated phospholipase A2 (Lp-PLA2)(hsCRP)
- Mean Lp-PLA2 activity level were 185 ± 48 nmol/mL/min
- Men and women showed a significant difference in their Lp-PLA2 levels (men: 201 nmol/mL/min and women: 166 nmol/mL/min)
- Had significant and direct correlation with BMI, waist circumference, diastolic BP, LDL-C, non-HDL-C, and plasma creatinine
- Had a significant and inverse correlation with HDL-C
- Had no significant correlations with blood glucose, systolic BP, hsCRP, and fibrinogen
- Both active smokers and non-smokers did not differ in the levels of their Lp-PLA2 activity
Findings: Subjects with MS in comparison to Subjects without MS (hsCRP)
- Had a significantly higher levels of both Lp-PLA2 and hsCRP
- hsCRP was 4.1 ± 3.3 mg/L versus 2.2 ± 3.2 mg/dL
- Lp-PLA2 was 198 ± 45 nmol/mL/min versus 180 ± 48 nmol/mL/min
- The levels of these markers increased as the number of components of metabolic syndrome increased